[Intraocular triamcinolone for diffuse diabetic macular edema].
BACKGROUND
The aim of the study was to evaluate the effect of an intravitreal injection of triamcinolone acetonide on the visual acuity of patients suffering from diffuse diabetic macular edema.


METHODS
The prospective, clinically interventional, uncontrolled study included 32 eyes (26 patients) with diffuse diabetic macular edema and received an intravitreal injection of 25 mg triamcinolone acetonide. Visual acuity was 0.12+/-0.08 (min.-max. 0.03-0.3; median 0.1) at baseline. Mean follow-up was 6.8+/-4.3 months.


RESULTS
Visual acuity increased to 0.17+/-0.11 (min.-max.: 0.03-0.4; median 0.125) after 4 weeks (p=0.009) and reached a mean maximum of 0.20+/-0.14 (min.-max.: 0.03-0.5; median 0.16) after 8 weeks (p=0.006). Later, visual acuity showed a slow decrease, but was significantly higher than at baseline up to 6 months postoperatively and 26 eyes (81.3%) gained in visual acuity. Ten eyes (31.2%) developed steroid-induced secondary ocular hypertension.


CONCLUSIONS
An intravitreal injection of 25 mg of triamcinolone acetonide may be an option in the treatment of diffuse diabetic macular edema.
Degenring
R F
RF
Fakultät für Klinische Medizin Mannheim der Ruprecht-Karls-Universität Heidelberg, Universitäts-Augenklinik Mannheim. robert.degenring@augen.ma.uni-heidelberg.de
Kreissig
I
I
Jonas
J B
JB
D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007267:Injections; D008266:Macula Lutea; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000139:chemically induced; D011446:Prospective Studies; D013997:Time Factors; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000009:adverse effects; D014792:Visual Acuity; D014822:Vitreous Body
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D014222:Triamcinolone Acetonide